Core Viewpoint - China Antibody-B (03681) has seen a significant increase in stock price, rising over 5% and reaching HKD 2.04, with a trading volume of HKD 13.36 million, following the publication of its preclinical study on the novel anti-IL-17RB antibody SM17 in a European respiratory journal [1] Group 1 - The preclinical study of SM17 demonstrates its potential to significantly improve the pathological features of chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF) through dual inhibition of the Th2/Th17 pathways and antifibrotic activity [1] - The Chairman and CEO of China Antibody expressed excitement over the publication, highlighting SM17's potential as a groundbreaking therapy for CRSwNP and IPF [1] - SM17 targets key upstream alarmin IL-25 and may provide a multifaceted treatment strategy for CRSwNP and IPF by simultaneously addressing Th2 inflammation, Th17 differentiation, and fibrosis, potentially filling the unmet needs in current downstream effector therapies [1]
港股异动 | 中国抗体-B(03681)再涨超5% SM17临床前研究凸显治疗CRSwNP和IPF强大潜力